BridgeMD
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia.
EU CTIS ID: 2024-510696-38-00
What this study is testing
To evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting TG from Baseline.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification.
- 2. Patients must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study.
- 3. 18 Years and older (Adult, Older Adult).
You likely can't join if
- 1. Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening.
- 2. Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal.
- 3. Total bilirubin > upper limit of normal unless due to Gilbert's syndrome.
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- Turkey
- United Kingdom
- New Zealand
- United States
- Canada
- Israel
- South Africa
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; Turkey; United Kingdom; New Zealand; United States; Canada and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.